Clinical trials: Cannabis
Marijuana Abuse
The Effect of Food on the Oral Bioavailability of AEF0117 in Healthy Volunteers
Cannabis use is increasing and will only further escalate with legalization of recreational and medical cannabis use in western countries , with a prevalence greater than 30 % in the US and most European countries for individuals…
- Trial name
- NCT05451017
- Testing
- 3ß-(4-methoxybenzyloxy)pregn-5-en-20-one in fed condition, 3ß-(4-methoxybenzyloxy)pregn-5-en-20-one in fasting condition
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Aelis Farma
Health, Subjective, Inflammatory Response
Efficacy and Safety of Hemp-derived, Full Spectrum Cannabigerol (CBG) in Adults
The goal of this observational study is to provide exploratory research into the in vivo physiological and psychological effects, if any, of cannabigerol (CBG) in healthy human adults age 21 or over.
- Conditions
- Health, Subjective, Inflammatory Response, Adverse Effect, Side Effect
- Trial name
- NCT05743985
- Testing
- Cannabigerol
- Where
- 6 sites in United States, Puerto Rico
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Formula30A LLC
Cannabis Withdrawal
Effect of PP-01 on Cannabis Withdrawal Syndrome
This study will be a randomized, double-blind, placebo-controlled, multicenter trial conducted to evaluate whether PP-01 mitigates the withdrawal symptoms associated with discontinuing cannabis in participants with moderate to…
- Trial name
- NCT05494437
- Testing
- PP-01 High Dose, PP-01 Low Dose, Nabilone
- Where
- 18 sites in United States
- Volunteers
- 234 people
- Sponsor
- PleoPharma, Inc.
Cancer Pain, Quality of Life
Safety and Efficacy of Inhaled Cannabis For the Uncontrolled Pain Relief in Patients With Advanced Cancer
This phase 2 multicenter clinical trial assess the safety and efficacy of inhaled PPP001 to relieve the pain in 78 advanced cancer patients with uncontrolled symptoms.
- Conditions
- Cancer Pain, Quality of Life, Pain, Acute, Cannabis Use
- Trial name
- PLENITUDE (NCT04042545)
- Testing
- PPP001
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- Tetra Bio-Pharma
Agitation,Psychomotor, Disruptive Behavior
A Medical Cannabis Oil for Treatment of Agitation and Disruptive Behaviors in Subjects With Dementia.
This double-blind, placebo-controlled study is designed to assess the effectiveness of, MediCane's medical cannabis oil extracted from MediCane's proprietary strain into GMP-grade olive oil, as an add-on therapy to standard of…
- Conditions
- Agitation,Psychomotor, Disruptive Behavior, Dementia, Alzheimer Disease
- Trial name
- NCT06217146
- Testing
- Medical Cannabis
- Where
- 3 sites in Israel
- Volunteers
- 24 people
- Sponsor
- M. H MediCane Ltd.
Head and Neck Squamous Cell Carcinoma
A Pharmacokinetic Study of Single Doses of Sativex in Treatment-induced Mucositis
To investigate what the body does to single doses of Sativex (i.e. the pharmacokinetics [PKs] of four sprays containing 10.8 mg Δ9 tetrahydrocannabinol [THC] and 10 mg cannabidiol [CBD]) when mild, moderate or severe oral…
- Trial name
- NCT01975688
- Testing
- Sativex
- Where
- United Kingdom
- Volunteers
- 10 people
- Sponsor
- GW Pharmaceuticals Ltd
Agitation Related to Dementia
The Effect of Cannabis on Dementia Related Agitation and Aggression
The most common syndrome in patients with severe dementia is agitated behavior, which is often characterized by a combination of violent behavior (physical or verbal), restlessness, and inappropriate loudness.
- Trial name
- NCT03328676
- Testing
- Cannabis
- Where
- Israel
- Volunteers
- 64 people
- Sponsor
- TO Pharmaceuticals
Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a Known Inducer of CYP3A4, Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a Potent Inhibitor of CYP3A4
Study to Evaluate the Effect of Rifampicin, Ketoconazole, and Omeprazole on the Pharmacokinetics of Sativex
Study to assess the effect of rifampicin, ketoconazole and omeprazole on the pharmacokinetics of a single dose of Sativex and to evaluate the safety of Sativex when given in combination with these other drugs.
- Conditions
- Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a Known Inducer of CYP3A4, Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a Potent Inhibitor of CYP3A4, Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a CYP2C19 Inhibitor
- Trial name
- NCT01323465
- Testing
- Sativex and rifampicin, Sativex and ketoconazole, Sativex and omeprazole
- Where
- United Kingdom
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Jazz Pharmaceuticals
Marijuana Abuse
Study of [4-14C] AEF0117 Following a Single Oral Dose in Healthy Male Subjects
Cannabis use is increasing and will only further escalate with legalization of recreational and medical cannabis use in western countries , with a prevalence greater than 30 % in the US and most European countries for individuals…
- Trial name
- NCT05554926
- Testing
- AEF0117
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Aelis Farma
Cannabis Use, Cachexia; Cancer
Safety and Efficacy of Inhaled Synthetic THC/CBD for Improving Physical Functioning and for Modulating Cachexia Progression in Patients With Advanced Cancer and Associated Cachexia
A large number of patients with advanced cancer also suffer from cachexia. Cachexia is a syndrome characterized by loss of skeletal muscle mass (with/or without loss of fat mass) that cannot be reversed by nutritional support and…
- Conditions
- Cannabis Use, Cachexia; Cancer, Advanced Cancer
- Trial name
- SERENITY (NCT04001010)
- Testing
- PPP011
- Where
- Canada
- Volunteers
- 334 people
- Sponsor
- Tetra Bio-Pharma
Pain, Pain Syndrome
Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Traumatic or Post-operative Peripheral Neuropathy
Over the last years a rising medical need for treatment of chronic pain was identified. Based on previous findings indicating the pain modulating effects of cannabinoids in chronic pain disorders, this clinical trial investigates…
- Conditions
- Pain, Pain Syndrome, Pain, Chronic, Chronic Pain
- Trial name
- NCT06071936
- Testing
- Adezunap (AP707)
- Where
- Germany
- Volunteers
- 558 people
- Sponsor
- Apurano Pharmaceuticals GmbH
Driving Under the Influence, Marijuana Intoxication
Cannabis Impairment Detection Application (CIDA)
Subjects will participate in a 4-visit study protocol in which they will be asked to complete a set of computerized tasks and a 45-minute simulated drive in a driving simulator.
- Conditions
- Driving Under the Influence, Marijuana Intoxication, Alcohol Intoxication
- Trial name
- CIDA (NCT04230460)
- Testing
- Cannabis (High% THC) (Inhaled), Cannabis (Very High% THC) (Inhaled), Alcohol (oral)
- Where
- United States
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- Advanced Brain Monitoring, Inc.
Palliative Care, Pain
A Study of Sativex® for Pain Relief in Patients With Advanced Malignancy
The purpose of this study is to determine whether Sativex® and GW-2000-02 are effective in the management of subjects with intractable cancer-related pain.
- Conditions
- Palliative Care, Pain, Cancer
- Trial name
- SPRAY (NCT00674609)
- Testing
- Sativex®, THC Alone
- Where
- United Kingdom
- Volunteers
- 177 people
- Sponsor
- Jazz Pharmaceuticals
Generalized Anxiety Disorder
Anxiety Symptoms in Relation to Use of Hemp-derived, Full Spectrum Cannabidiol (CBD)
Generalized anxiety disorder affects about 6.8 million adults in the United States, therefore its treatment is of major public health interest.
- Trial name
- NCT05023759
- Testing
- Formula30A Full Spectrum Hemp Cannabidiol 25mg Capsules
- Where
- 6 sites in United States, Puerto Rico
- Volunteers
- 30 people
- Sponsor
- Formula30A LLC
Pain, Advanced Cancer
Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer
This 9-week study aimed to determine the efficacy, safety, and tolerability of nabiximols (Sativex®) as an adjunctive treatment, compared with placebo in relieving uncontrolled persistent chronic pain in participants with…
- Trial name
- SPRAY III (NCT01361607)
- Testing
- Nabiximols
- Where
- 68 sites in United States, Bulgaria and 8 more
- Volunteers
- 399 people
- Sponsor
- Jazz Pharmaceuticals
Pain
A Study of Cannabis Based Medicine Extracts and Placebo in Patients With Pain Due to Spinal Cord Injury
A study to investigate the effects of sublingual cannabis based medicine extracts on neuropathic pain associated with spinal cord injury.
- Trial name
- NCT01606202
- Testing
- GW-1000-02
- Where
- United Kingdom
- Volunteers
- 116 people
- Sponsor
- Jazz Pharmaceuticals
Long COVID
Feasibility of Cannabidiol for the Treatment of Long COVID
This is an open label, phase 2 clinical trial to assess the feasibility of a cannabidiol (CBD) dominant medicinal cannabis for the treatment of Long COVID.
- Trial name
- NCT04997395
- Testing
- MediCabilis Cannabis sativa 50
- Where
- United Kingdom
- Volunteers
- 12 people
- Sponsor
- Bod Australia
Cannabis Intoxication
Cannabis Impairment Detection Device Study
The goal of this study is to develop a cannabis impairment detection device in adult cannabis users. The main question[s] it aims to answer are: Is the investigational device accurate and reliable at detecting cannabis…
- Trial name
- NCT07122349
- Testing
- Cannabis Impairment Test
- Where
- Canada
- Volunteers
- 362 people, healthy volunteers welcome
- Sponsor
- Gaize
Pain, Pain Syndrome
Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Central Neuropathy of Any Genesis
Over the last years a rising medical need for treatment of chronic pain was identified. Based on previous findings indicating the pain modulating effects of cannabinoids in chronic pain disorders, this clinical trial investigates…
- Conditions
- Pain, Pain Syndrome, Pain, Chronic, Chronic Pain
- Trial name
- NCT06071949
- Testing
- Adezunap
- Where
- Germany
- Volunteers
- 558 people
- Sponsor
- Apurano Pharmaceuticals GmbH
Osteoarthritis, Knee
Cannabinoid Profile Investigation of Vapourized Cannabis in Patients With Osteoarthritis of the Knee
Primary Objective: To determine the analgesic dose-response characteristics of vapourized cannabinoids with varying degrees of delta-9-tetrahydrocannabiol (THC)/ Cannabidiol (CBD) ratios.
- Trial name
- CAPRI (NCT02324777)
- Testing
- Cannabis, Volcano® Medic Vapourizer
- Where
- 2 sites in Canada
- Volunteers
- 40 people
- Sponsor
- Prairie Plant Systems Inc.